T cells from patients with melanoma can trigger a protective immune response against the disease according to a new study out of University Hospitals Case Medical Center Seidman Cancer Center and Case Western Reserve University School of Medicine.
MRV Research
Trovagene (TROV) Announces Launch of PCM Technology-Related Study in Advanced Melanoma Response Prediction
Trovagene (NASDAQ: TROV) announced the launch of a study that aims to determine utility of the Company’s Precision Cancer Monitoring (PCM) technology for predicting response to treatment in advanced melanoma patients receiving one or a combination of the novel immunotherapy agents Yervoy® (ipilumumab), a CTLA-4 inhibitor, and Opdivo® (nivolumab), a PD-1 inhibitor.
New Treatment for Melanoma Uses a Form of the Herpes Virus
The American Cancer Society estimates that about 74,000 Americans will be diagnosed with melanoma this year and almost 10,000 will die from this deadliest form of skin cancer. Over the past several years, treatment of advanced cases of melanoma has been transformed as new FDA-approved therapies developed by several different companies have come onto the market. An FDA advisory committee recently approved a therapy that takes a totally novel approach that involves injecting a live attenuated virus directly into regionally or distant metastatic melanoma tumors.
History of melanoma, actinic skin lesions linked to better use of sun protection
A recent population-based study has revealed that people with a previously confirmed melanoma diagnosis and/or treated actinic lesions were more likely to regularly use sun protection and skin exam practices, according to a recent study.